Search clinical trials for: Xolair (omalizumab)

Total 571 results

Hoffmann-La Roche

Completed

A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal Polyps (POLYP 1)

Nasal Polyps | Chronic Rhinosinusitis

Czechia, United States, Portugal, Germany, Canada, Ukraine, Poland, Mexico, Russian Federation, United Kingdom
NYU Langone Health

Terminated

Sputum-derived Cellular Targets After Xolair (Omalizumab)

Asthma

United States
Charite University, Berlin, Germany
Novartis Pharmaceuticals

Completed

Urticaria Facticia Treatment With Omalizumab (UFO) (UFO)

Symptomatic Dermographism

Germany
Yuhan Corporation

Recruiting

A Single Dose, Phase 1 Study of YH35324 in Patients With Various Allergic Diseases

Allergic Disease | Chronic Spontaneous Urticaria | Cold Urticaria | Chronic Inducible Urticaria

Korea, Republic of
Hoffmann-La Roche

Completed

A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitus With Nasal Polyps (POLYP 2)

Nasal Polyps | Chronic Rhinosinusitis

Spain, United States, Belgium, France, Poland, Hungary, Finland, Mexico, Russian Federation, Ukraine
National Institute of Allergy and Infectious Diseases...
Immune Tolerance Network (ITN)

Completed

Omalizumab (Xolair) and Allergy Shots For the Treatment of Seasonal Allergies

Hypersensitivity | Allergy | Rhinitis | Hay Fever

United States
Charite University, Berlin, Germany
Novartis Pharmaceuticals

Completed

Cold Urticaria Treatment With Xolair (CUTEX)

Cold Contact Urticaria

Germany
Novartis

Completed

Safety and Tolerability of Omalizumab in Patients With Mild to Moderate Asthma

Asthma

Germany, South Africa
National Institute of Allergy and Infectious Diseases...
Inner-City Asthma Consortium

Completed

Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations (PROSE)

Asthma

United States
University of California, Davis

Not yet recruiting

Efficacy and Safety of Rituximab Combined With Omalizumab in Patients With Bullous Pemphigoid

Bullous Pemphigoid

United States
David Lang
Genentech, Inc.

Completed

Therapeutic Utility of Xolair in Patients Undergoing Aspirin Desensitization

Aspirin Sensitivity

United States
Genentech, Inc.

Completed

A Study Evaluating the Persistency of Response With or Without Xolair (Omalizumab) After Long-term Therapy (XPORT)

Allergic Asthma

United States
Novartis

Completed

Efficacy and Safety of Omalizumab in Adults (18-70 Years) With Moderate to Severe Chronic Urticaria

Chronic Urticaria

Germany
Celltrion

Completed

To Compare Efficacy and Safety of CT-P39 and EU-approved Xolair in Patients With Chronic Spontaneous Urticaria (omalizumab)

Chronic Spontaneous Urticaria

Poland
Xiu-Min Li

Unknown

E-B-FAHF-2, Multi OIT and Xolair (Omalizumab) for Food Allergy

Food Allergy

United States
Amgen

Completed

Study to Evaluate Tezepelumab in Adults With Chronic Spontaneous Urticaria (INCEPTION)

Chronic Spontaneous Urticaria

United States, Korea, Republic of, Spain, Italy, Canada, Poland, Japan, France, Greece, Germany
National Institute of Allergy and Infectious Diseases...

Completed

A Randomized, Double-Blind, Placebo-Controlled Study of Omalizumab for Idiopathic Anaphylaxis

Hypotension | Angioedema | Anaphylaxis | Bronchospasm

United States
Clinica Universidad de Navarra, Universidad de...
Hospital Clinic of Barcelona; Hospital Regional de Malaga

Unknown

Similarities and Differences of Biological Therapies for Severe Asthma.

Asthma

Spain
University of Iowa
Genentech, Inc.

Completed

Efficacy and Safety of Omalizumab in Bullous Pemphigoid

Bullous Pemphigoid

United States
Medical University of Silesia
Centrum Medyczne Andrzej Bożek

Not yet recruiting

Biologics and Sublingual Immunotherapy (BSIPL)

Asthma, Allergic
Novartis Pharmaceuticals

Completed

Omalizumab in Chronic Spontaneous Urticaria Patients Non Responding to Initial Standard antihistaminE Treatment (SUNRISE)

CHRONIC SPONTANEOUS URTICARIA

France
Novartis

Completed

A Compassionate Access Protocol to Assess the Safety of XolairTM (Omalizumab) in Patients (≥ 6 Years Old) With Severe Allergic Asthma Who Remain Symptomatic Despite Optimal Therapy

Asthma

Canada
Novartis
Genentech, Inc.; Tanox

Completed

Open Label Study to Assess Safety and Immunogenicity of Omalizumab Liquid Formulation.

Asthma

United States, Argentina, Germany
Bernstein Clinical Research Center

Withdrawn

A Pilot Study Investigating the Effect of Omalizumab (Xolair) in Work-Related Animal Induced Asthma

Allergy Induced Asthma
The University Clinic of Pulmonary and Allergic...

Unknown

Omalizumab Treatment in Venom Immunotherapy With Systemic Reactions

Allergy | Immunotherapy | Omalizumab | Bee Venom

Slovenia
Stanford University

Completed

Single Center Study Using Omalizumab in Subjects With Atopic Dermatitis (OXAD)

Atopic Dermatitis

United States
Novartis Pharmaceuticals

Completed

Pharmacokinetics and Pharmacodynamics, Efficacy and Safety of Omalizumab in Japanese Children (6 - 15 Years)

Allergic Asthma

Japan
Genentech, Inc.

Completed

A Study of Xolair in Peanut-Allergic Subjects Previously Enrolled in Study Q2788g

Peanut Hypersensitivity
MedImmune LLC

Completed

A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL

Allergic Rhinitis | Healthy Volunteers | Atopic Dermatitis | Allergic Asthma

United States
Novartis Pharmaceuticals

Completed

A Study Evaluating the Efficacy of QGE031 Compared to Omalizumab in Patients With Allergic Asthma

Allergic Asthma

Canada, Sweden
National Institute of Allergy and Infectious Diseases...
Genentech, Inc.; Novartis Pharmaceuticals; Rho Federal Systems Division, Inc.

Active, not recruiting

Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants (OUtMATCH)

Peanut Allergy | Multi-food Allergy

United States
Kashiv BioSciences, LLC

Recruiting

PK, PD, Safety & Immunogenicity of ADL-018 Lyo in Healthy Adult Subjects

Healthy

India
Syneos Health
CuraTeQ Biologics Private Ltd.

Completed

Biosimilar Study Comparing PK, PD, Safety and Immunogencity of BP11 With US Licensed Xolair and EU Approved Xolair

Healthy Volunteers

New Zealand, Australia
Mayo Clinic
Genentech, Inc.

Withdrawn

Xolair (Omalizumab) for Treatment of Drug-induced Acute Tubulointerstitial Nephritis (AIN)

Acute Interstitial Nephritis

United States
Rigshospitalet, Denmark
Zealand University Hospital; Novartis; Hvidovre University Hospital; Herlev Hospital

Active, not recruiting

Treatment With the Anti-IgE Monoclonal Antibody Omalizumab in Women With Asthma Undergoing Fertility Treatment. - A Proof of Concept Study. (PRO_ART)

Asthma | Infertility, Female

Denmark
Novartis Pharmaceuticals

Completed

Effect of Omalizumab in Patients With Severe Persistent Non-atopic Uncontrolled Asthma (NATAIR)

Asthma

France
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Not yet recruiting

Study to Evaluate the Therapeutic Equivalence of SYN008 Versus Xolair® in the Treatment of Patients With Refractory Chronic Spontaneous Urticaria

Chronic Spontaneous Urticaria
Selina Gierer, D.O.

Withdrawn

Sustained Effect of Urticaria Remission With Relatively High Dose Vitamin D Supplementation After Omalizumab Discontinuation

Urticaria

United States
Philippe Bégin
The Hospital for Sick Children; Centre de recherche du Centre hospitalier universitaire... and other collaborators

Recruiting

Omalizumab to Accelerate a Symptom-driven Multi-food OIT (BOOM)

Immunotherapy | Physiological Effects of Drugs | Food IgE-mediated Allergy | Omalizumab

Canada
University of Florida

Completed

The Effect of Omalizumab on Airway Responsiveness to Adenosine in Patients With Poorly Controlled Asthma

Asthma

United States
Cliniques universitaires Saint-Luc- Université...
KU Leuven; University of Liege; University Hospital, Ghent; Universitair Ziekenhuis... and other collaborators

Recruiting

Study of Magnitude and Prediction of Response to Omalizumab and Mepolizumab in Adult Severe Asthma. (PREDICTUMAB)

Severe Asthma

Belgium
NYU Langone Health
Genentech, Inc.

Completed

Efficacy and Safety of Efalizumab in the Treatment of Moderate-Severe Hydradenitis Suppurativa

Hidradenitis Suppurativa

United States
Novartis Pharmaceuticals

Completed

OPTIMA: Efficacy of Optimized Re-treatment and Step-up Therapy With Omalizumab in Chronic Spontaneous Urticaria (CSU) Patients (OPTIMA)

Chronic Spontaneous Urticaria

Argentina, Dominican Republic, Canada, Brazil, Guatemala, Chile, Mexico, Panama
Genentech, Inc.

Completed

A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Plaque Psoriasis Involving the Hands and/or Feet

Psoriasis
Merck KGaA, Darmstadt, Germany

Completed

Efalizumab for Treatment of Patients With Moderate to Severe Psoriasis

Moderate to Severe Psoriasis

Switzerland
Genentech, Inc.

Completed

A Study to Evaluate Raptiva in Subjects With Chronic Moderate or Worse Plaque Psoriasis Who Have Had an Inadequate Response to an Anti-TNF Agent

Psoriasis
Genentech, Inc.

Completed

A Study to Evaluate Efalizumab in Adults With Plaque Psoriasis, Including Those Who Are Receiving Concomitant Antipsoriatic Therapies

Psoriasis
Norwegian University of Science and Technology

Terminated

Classification and Characterization of Patients Treated With Efalizumab for Plaque Psoriasis

Plaque Psoriasis

Norway
Washington University School of Medicine
Genentech, Inc.

Completed

Safety and Effectiveness of Efalizumab to Treat Oral Lichen Planus

Lichen Planus, Oral

United States
Genentech, Inc.

Completed

A Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihistamine Treatment (H1)

Chronic Idiopathic Urticaria

Search clinical trials for: Xolair (omalizumab)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Spain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations